Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #307105 on NorthWest Biotherapeutics Inc (NWBO)
sentiment_stocks
09/14/20 11:00 AM
#307198 RE: abeta #307105
H2R
09/14/20 11:28 AM
#307219 RE: abeta #307105
Breast Cancer - Off-Label - 2000-2007 Results 13,347 women were treated with 16,127 regimens (12% of women switched to a new regimen during followup). Sixty-four percent (10,391) of regimens were off-label/supported, 25% (3,987) were on-label and 11% (1,749) were off-label/unsupported. Drugs never supported for breast cancer accounted for 19% of off-label/unsupported use and 1% of total use. Hospitalization/ER admission occurred in 32% of off-label/unsupported regimens, compared to 27% of off-label/supported and 25% of on-label regimens (p<.0001). Prevalence and safety of off-label use of chemotherapeutic agents in older breast cancer patients: estimates from SEER-Medicare data 2016 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827612/ abeta post